(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 15.8B | +8% |
Gross Profit | 12.2B | - |
Cost Of Revenue | 3.5B | -10% |
Operating Income | 5.7B | -377% |
Operating Expenses | 6.6B | - |
Net Income | 4.8B | -488% |
R&D | 4B | -59% |
G&A | 2.5B | -11% |
Interest Expense | 303MM | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
RAHWAY, N.J., July 26, 2024--Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Advanced Bladder Cancer
Clesrovimab was found to reduce the instances of RSV-linked, medically attended lower respiratory infection up to day 150.
On Tuesday, Merck & Co Inc (NYSE:MRK) shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease. Clesrovimab met its primary safety and efficacy endpoints in the trial, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150. Participants were randomized to
RAHWAY, N.J., July 23, 2024--Merck Announces Fourth-Quarter 2024 Dividend
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin.
Key Insights Significantly high institutional ownership implies Merck's stock price is sensitive to their trading...
The drug, a rival to Sanofi and AstraZeneca’s fast-selling Beyfortus, met its main goals in a Phase 3 trial. But undisclosed study results leave its full potential unclear.
RAHWAY, N.J., July 23, 2024--Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody for Infants
Applications for nanotechnology in medicine include imaging, diagnosis, or the delivery of drugs that will help medical professionals treat various diseases.